Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

UGN-103

Small molecule · developed by UroGen Pharma

Phase 3 Most advanced trial (none active)
URGN Developer
1 Registered trials

What is UGN-103?

UGN-103 is a sustained-release reverse thermal hydrogel formulation of mitomycin C, given by intravesical instillation. The liquid forms a gel that conforms to the bladder wall, where mitomycin C alkylates DNA and produces interstrand cross-links that inhibit DNA synthesis. It is studied in bladder cancer and urothelial carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Pathways
DNA cross-linking, inhibition of DNA synthesis, inhibition of tumor cell proliferation
Therapy area
Oncology
Developer
UroGen Pharma Ltd. (URGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06331299 Phase 3 Bladder Cancer Completed URGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder

More from UroGen Pharma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the URGN page.

Follow URGN, the company behind UGN-103

See URGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

URGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.